Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Juno Therapeutics is developing blood cancer treatments. Photo: BSIP/UIG via Getty Images
Celgene is in discussions to buy Juno Therapeutics roughly a week after agreeing to acquire a separate drug company, the Wall Street Journal reports. Juno's market cap was $5.2 billion at the end of Tuesday, and its stock jumped more than 43% in after-hours trading, suggesting a deal value of about $7.5 billion.
Get smart: Celgene, which already had a relationship with Juno, wants to own a piece of CAR-T treatments, which use a person's own immune cells to fight off cancer and are expensive. Celgene also appears to be prepping itself for 2027, when its blockbuster blood cancer drug Revlimid loses U.S. patent protection.